Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2456169 | 0.75 | CCR1 (0.37) | — | |
| SCHEMBL11312613 | 0.74 | NPC1 (0.36) | NPC1RAB9A | |
| SCHEMBL19691765 | 0.70 | BTK (0.47) | NPC1RAB9A | |
| SCHEMBL2043379 | 0.70 | ALDH1A1 (0.47) | NPC1RAB9A | |
| SCHEMBL6866817 | 0.70 | — | — | |
| SCHEMBL6866822 | 0.70 | F2RL1 (0.31) | — | |
| SCHEMBL12458263 | 0.70 | NPC1 (0.36) | NPC1RAB9A | |
| SCHEMBL6866370 | 0.70 | TMIGD3 (0.39) | — | |
| SCHEMBL2928851 | 0.69 | — | — | |
| SCHEMBL28856068 | 0.69 | CCR1 (0.47) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4017844-B1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF INFECTIOUS DISEASES AND CANCER | AC BIOSCIENCE SA (CH) | 2024-01-24 | — | — | EP | disclosed |
| EP-4017844-B1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF INFECTIOUS DISEASES AND CANCER | AC BIOSCIENCE SA (CH) | 2024-01-24 | — | — | EP | disclosed |
| US-20220306587-A1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF INFECTIOUS DISEASES AND CANCER | AC BIOSCIENCE SA (CH) | 2022-09-29 | — | — | US | disclosed |
| CN-114555567-A | Compounds and their use for the treatment of infectious diseases and cancer | AC生命科学有限公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2021032857-A1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF INFECTIOUS DISEASES AND CANCER | AC BIOSCIENCE SA (CH) | 2021-02-25 | — | — | WO | disclosed |
| US-8927738-B2 | 2-arylimidazole derivatives as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2015-01-06 | — | — | US | disclosed |
| US-8927738-B2 | 2-arylimidazole derivatives as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2015-01-06 | — | — | US | disclosed |
| EP-2513105-B1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | LUNDBECK & CO AS H (DK) | 2014-05-14 | — | — | EP | disclosed |
| EP-2513105-B1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | LUNDBECK & CO AS H (DK) | 2014-05-14 | — | — | EP | disclosed |
| US-20130289038-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2013-10-31 | — | — | US | disclosed |
| US-20130289038-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2013-10-31 | — | — | US | disclosed |
| US-8501797-B2 | (2-aryl-1H-imidazol-4-yl)-linked heterocycle derivatives | H. LUNDBECK A/S (DK) | 2013-08-06 | — | — | US | disclosed |
| US-8501797-B2 | (2-aryl-1H-imidazol-4-yl)-linked heterocycle derivatives | H. LUNDBECK A/S (DK) | 2013-08-06 | — | — | US | disclosed |
| US-8501797-B2 | (2-aryl-1H-imidazol-4-yl)-linked heterocycle derivatives | H. LUNDBECK A/S (DK) | 2013-08-06 | — | — | US | disclosed |
| US-20120302548-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2012-11-29 | — | — | US | disclosed |
| US-20120302548-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2012-11-29 | — | — | US | disclosed |
| US-20120302548-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2012-11-29 | — | — | US | disclosed |
| WO-2011072696-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289038-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | PDE12, PDE3B, PDE5A | NPC1 1012/4885RAB9A 899/4885 |
| US-20220306587-A1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF INFECTIOUS DISEASES AND CANCER | SGPL1, SPHK1, S1PR1 | NPC1 152/4885RAB9A 3546/4885 |
| US-20120302548-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | PDE12, PDE3B, PDE5A | NPC1 1012/4885RAB9A 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.